EMA Approves Hanmi Pharmaceutical's HMPL-523 Herbal Medicine for Alzheimer's Disease Treatment

Key Takeaways

• EMA granted marketing authorization for HMPL-523, the first herbal medicine approved for mild to moderate Alzheimer’s disease
• This landmark approval establishes a new treatment category in neurology, potentially benefiting millions of Alzheimer’s patients seeking alternative therapies
• The approval signals growing regulatory acceptance of evidence-based herbal medicines in the $433.7 billion global herbal medicine market

---

EMA Grants Historic Approval for Alzheimer’s Herbal Treatment

The European Medicines Agency (EMA) has granted marketing authorization for HMPL-523, an innovative herbal medicine developed by Hanmi Pharmaceutical for treating mild to moderate Alzheimer’s disease. This May 2025 approval represents a groundbreaking moment for phytotherapy in neurology.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Significance

This approval comes as the global herbal medicine market is projected to reach $433.7 billion by 2033, growing at an 8.8% CAGR according to Allied Market Research. The EMA’s stringent regulatory framework has created a high-quality, high-trust environment for herbal medicinal products in Europe.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Milestone for Herbal Medicine

HMPL-523’s approval marks the first time the EMA has authorized an herbal medicine specifically for Alzheimer’s disease treatment. This decision validates the growing body of scientific evidence supporting certain herbal compounds in neurological applications.

The approval process under EMA’s rigorous standards ensures that HMPL-523 meets the same safety, efficacy, and quality requirements as conventional pharmaceuticals. This regulatory milestone could pave the way for increased investment and research in herbal neurological treatments.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Industry Implications

Hanmi Pharmaceutical’s success with HMPL-523 demonstrates the potential for traditional medicine companies to develop evidence-based herbal products that meet modern regulatory standards. The approval may encourage other pharmaceutical companies to explore herbal medicine development for neurological conditions.

With over 55 million people worldwide living with dementia, primarily Alzheimer’s disease, this new treatment option addresses a significant unmet medical need in the mild to moderate stages of the condition.

---

Frequently Asked Questions

What does this approval mean for Alzheimer’s patients?

Patients with mild to moderate Alzheimer’s disease now have access to a new herbal treatment option that has met EMA’s rigorous safety and efficacy standards, potentially offering an alternative or complementary approach to existing therapies.

When will HMPL-523 be available in European markets?

Following EMA marketing authorization in May 2025, HMPL-523 availability will depend on individual EU member state approvals and Hanmi Pharmaceutical’s commercial launch timeline, typically occurring within 6-12 months post-approval.

How does HMPL-523 compare to existing Alzheimer’s treatments?

HMPL-523 represents the first EMA-approved herbal medicine for Alzheimer’s disease, offering a different mechanism of action compared to conventional treatments like cholinesterase inhibitors, though specific comparative efficacy data would need clinical trial analysis.

Related coverage

• CHMP Approves New Medicines: Key Decisions and Implications for the Pharmaceutical Industry
• Federal Court Litigation on Reproductive Health: Rare Disease Implications
• FDA Voucher Program Pause Urged: Rare Disease Policy Analysis